Significantly, mTOR inhibitors, the only approved pharmacological therapy for SEGA, were also observed in the gene-drug list, further validating our approach and supporting the potential of our model to detect clinically relevant therapies. The gene discussed is MTOR; the disease is subependymal giant cell astrocytoma.